Press Releases

Boston, Ma, Nov. 12, 2024 – Syner-G BioPharma Group, a leading provider of regulatory strategy, product development, and medical writing solutions for the life science industry, is thrilled to announce that it has been named one of the 2025 Best Places to Work by BioSpace. This recognition highlights Syner-G’s commitment to fostering a supportive, innovative, and inclusive work environment that empowers its employees and fuels the company’s continued growth and excellence. Ron Kraus, Chief Executive Officer of Syner-G, expressed his gratitude and pride in receiving this accolade: “We are honored to be recognized by BioSpace for the second year in a row as one of the best places to work

Two Leading Consultancies Unite to Deliver Comprehensive, Integrated Solutions for Life Science Organizations Worldwide   Boston, Sept. 18th, 2024 — Sequoia Biotech Consulting (Sequoia), a leading life sciences consultancy helping organizations to scale rapidly and to deliver high-quality therapeutics, and Syner-G BioPharma Group, a leading provider of integrated regulatory and biopharmaceutical development services, are excited to announce a strategic combination. This merger will expand and enhance the comprehensive services offered to clients across the pharmaceutical, biotechnology, and medical device sectors.   The combination forms a market leading organization with approximately 500 employees, combining expertise in process and analytical development, regulatory strategy, submissions support, quality and compliance, operational excellence, program management,

November 8, 2023, Boston, MA Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, announced today that it has been named a BioSpace 2024 Best Place to Work. “I am thrilled and honored that Syner-G has been recognized as a 2024 Biospace Best Places to Work,” said Ron Kraus, CEO at Syner-G. “This recognition is a testament to the dedication and passion of our incredible team. We are excited about what the future holds and look forward to further enhancing our culture of excellence.” Syner-G is thrilled to have been included in the small employer category. “We believe that

Murray to Spearhead Newly Integrated Department October 26, 2023, Boston, MA —Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, announced the addition of Kristin Murray as senior vice president of regulatory consulting services. “I am thrilled to join this forward-thinking company, whose expansion is vital to the biopharma sector,” said Murray. “I look forward to guiding the team of dedicated experts who are deeply passionate about their work.” Murray will lead a newly integrated department providing a comprehensive suite of regulatory consulting services. As Syner-G continues to grow, bringing in a results-oriented leader with demonstrated success in developing

Bringing Depth and Breadth of Biotech Experience to Oversee Continued Growth BOSTON (PRWEB) APRIL 06, 2023 – Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, today announced the addition of Neil Butera as chief commercial officer. This hire deepens the bench of the C-suite team in response to the company’s continued growth. “We are thrilled to have Neil join the Syner-G team,” said Ron Kraus, chief executive officer, Syner-G. “His proven commercial experience in the bio-tech industry is an invaluable asset to the current leadership team. We look forward to seeing the unique ways he will propel our

Expands Expertise in Biologics and Builds Scale in CMC and Quality Consulting Boston, MA, January 19, 2023 – Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of RMC Pharmaceutical Solutions (RMC). Based in Boulder, CO, RMC supports the outsourced CMC and Quality needs of biotech and pharma companies across multiple therapeutic areas. The acquisition provides additional depth to Syner-G’s suite of pharmaceutical science services, adding impressive development experience in all biologic modalities including cell and gene therapy. The combined team offers an impressive range of process and analytical development services, regulatory strategy, regulatory submission

Rapid Growth Drives the Need for an Investment in Talent   January 10, 2023, Boston, MA — Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to the pharmaceutical and medical device industries, today announced that Karen Casey has joined the organization as the chief people officer. “We are thrilled to welcome Karen Casey into the Syner-G family,” shared Syner-G BioPharma Group CEO, Ron Kraus. “We are a people business and to support our growth, we need an experienced leader to help build and retain a sophisticated workforce as well as build on our culture of excellence.” Casey has 27 years’ experience in human

RESEARCH TRIANGLE PARK, NC: 13 June 2022 Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). (more…)

RESEARCH TRIANGLE PARK, NC: 01 March 2022 – In the second half of 2021, IMPACT’s (now Syner-G BioPharma Group’s) employees continued their generous efforts via the Making an IMPACT (MAI) community service initiative. We continued our charitable and community outreach efforts by taking hybrid approaches to in-person and virtual service activities and celebrated our 6th annual Season of Giving campaign! (more…)

Boston, MA (February 1, 2022) – Syner-G BioPharma Group (“Syner-G” or the “Company”), a leading provider of Chemistry, Manufacturing, and Controls (“CMC”) technical, regulatory, and compliance consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of Impact Pharmaceutical Services (“IMPACT”). Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post-marketing of drugs and biologics. Both Syner-G and IMPACT have demonstrated strong track records of consistent growth and success in providing customized and highly complementary solutions to support the development of quality of life enhancing and lifesaving therapeutics. The combination